Fosfomycin: A Novel Epoxide Antimicrobial

Video
Conference|ID Week

Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a unique, novel antimicrobial.

Evelyn J. Ellis-Grosse, PhD, chief scientific officer of Zavante Therapeutics, explains why Zavante Therapeutic’s fosfomycin is a novel antimicrobial. She also shares what the drug’s unique mechanism of action is.

Recent Videos
Related Content
Long-Acting Lenacapavir Shows Efficacy in Heavily Treatment-Experienced Patients

Long-Acting Lenacapavir Shows Efficacy in Heavily Treatment-Experienced Patients

Sophia Abene
November 11th 2024
Article
From Pathogen to Infectious Disease Diagnosis: Taking on Potential Standard-of-Care Diagnostic Opportunities

From Pathogen to Infectious Disease Diagnosis: Taking on Potential Standard-of-Care Diagnostic Opportunities

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc
August 1st 2024
Podcast
What We Know But Still Have to Learn About Long COVID

What We Know But Still Have to Learn About Long COVID

Sophia Abene;Isabella Ciccone, MPH;Ravindra Ganesh, MD, MBBS, FACP, Dip ABOM;Monica Verduzco-Gutierrez, MD;Svetlana Blitshteyn, MD, FAAN
November 8th 2024
Article
From Pathogen to Infectious Disease Diagnosis

From Pathogen to Infectious Disease Diagnosis

Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc
July 12th 2024
Podcast
Trends in Carbapenemase-Producing Organisms: Prevalence, Treatment, and Outcomes

Trends in Carbapenemase-Producing Organisms: Prevalence, Treatment, and Outcomes

Sophia Abene;Kirby An, PharmD
November 7th 2024
Article
Infection Control: AP Technology's Impact on Reducing HAIs and AMR Pathogens

Infection Control: AP Technology's Impact on Reducing HAIs and AMR Pathogens

Sophia Abene;Deborah (Debbi) Birx, MD;Amy Carenza, BBA
November 6th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.